Myeloid neoplasms, including acute myeloid leukemia (AML), myeloproliferative neoplasms
(MPNs), and myelodysplastic syndromes (MDS), feature clonal dominance and remodeling …

Myeloproliferative neoplasms (MPNs) originate from genetically transformed hematopoietic
stem cells that retain the capacity for multilineage differentiation and effective myelopoiesis …

Patient outcome in primary myelofibrosis (PMF) is significantly influenced by karyotype. We
studied 879 PMF patients to determine the individual and combinatorial prognostic …

Purpose The Dynamic International Prognostic Scoring System (DIPSS) for primary
myelofibrosis (PMF) uses five risk factors to predict survival: age older than 65 years …

Background Myelofibrosis is a Philadelphia chromosome–negative myeloproliferative
neoplasm associated with cytopenias, splenomegaly, poor quality of life, and shortened …

We present a review of critical concepts and produce recommendations on the management
of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring …

Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell
count greater than 25× 109/L, peripheral blood blasts 1% or higher, and constitutional …

Purpose The WHO diagnostic criteria underscore the role of bone marrow (BM) morphology
in distinguishing essential thrombocythemia (ET) from early/prefibrotic primary myelofibrosis …

Disease overview: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN)
characterized by stem cell‐derived clonal myeloproliferation that is often but not always …

We studied the relationship between JAK2 (V617F) mutant allele burden and clinical
phenotype, disease progression and survival in patients with polycythemia vera (PV). The …